The EU-CARDIOPROTECTION COST Action (CA16225) is a pan-European research network of leading experts in experimental and clinical cardioprotection, whose overall aim is to improve the translation of novel experimental cardioprotective therapies into the clinical setting for patient benefit.
Next eventStellenbosch, South Africa
1 - 4 April 2019
6th Frontiers in Cardiovascular Research, Stellenbosch
Realizing the therapeutic potential of novel cardioprotective therapies: The EU-CARDIOPROTECTION COST Action – CA16225May 23, 2018 | General
Acute myocardial infarction (AMI) and the heart failure (HF) that often follows are the leading causes of death and disability in Europe and worldwide. As such, new treatment strategies are needed to protect the heart against acute ischemia/reperfusion injury (IRI) in order to preserve cardiac function and prevent adverse left ventricular remodeling and HF – […]